1256384-83-4

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1228968-83-9 tert-butyl (2S)-2-[5-(4'-bromobiphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidine-1-carboxylate 
• 72-18-4 L-valine 
• 1228968-82-8 (2S,4S)-2-(2-(4'-bromobiphenyl-4-yl)-2-oxoethyl) 1-tert-butyl pyrrolidine-1,2-dicarboxylate 
• 1228968-83-9 (S)-tert-butyl 2-(4-(4'-bromo-[1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 

Downstream Products

• 1241379-00-9 ((S)-1-{(S)-2-[5-(4'-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3H-benzoimidazol-5-yl}-biphenyl-4-yl)-1H-imidazol-2-yl]-pyrrolidine-1-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 
• 1352212-61-3 methyl {(2S)-3-methyl-1-oxo-1-[(2S)-2-{5-[4'-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)biphenyl-4-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]butan-2-yl}carbamate 
• 1446139-12-3 C₄₆H₅₂FN₇O₇ 

Relevant academic research and scientific papers

Benzimidazole-containing HCV NS5A inhibitors: Effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency

The treatment of HCV with highly efficacious, well-tolerated, interferon-free regimens is a compelling clinical goal. Trials employing combinations of direct-acting antivirals that include NS5A inhibitors have shown significant promise in meeting this challenge. Herein, we describe our efforts to identify inhibitors of NS5A and report on the discovery of benzimidazole-containing analogs with subnanomolar potency against genotype 1a and 1b replicons. Our SAR exploration of 4-substituted pyrrolidines revealed that the subtle inclusion of a 4-methyl group could profoundly increase genotype 1a potency in multiple scaffold classes.

HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS

Inhibitors of HCV replication of formula I, including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein R and R' have the meaning as defined herein. The present invention also relates to processes for preparing said compounds

ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS

Compounds represented by formula I as described herein or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1, R2, R2', R3, R3', R4, R4', R5, R5', m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

HEPATITIS C VIRUS INHIBITORS

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof; to compositions containing such compounds; and to the of such compounds as inhibitors of HCV replication.